Navigation Links
Biodel Inc. to Present at 29th Annual JPMorgan Healthcare Conference on January 13th, 2011
Date:1/6/2011

DANBURY, Conn., Jan. 6, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced that Dr. Errol De Souza, President and CEO of Biodel, will present a corporate update at the 29th Annual JPMorgan Healthcare Conference on Thursday, January 13, 2011 at 9:30 a.m. Pacific Time (12:30 p.m. Eastern Time). The update will include information about the development of new follow-on formulations of its lead product, Linjeta™, including milestones and timelines.

The JPMorgan Healthcare Conference will be held January 9-13, 2011, at the Westin St. Francis Hotel in San Francisco, California.

Interested parties may access the presentation in the investor relations section of Biodel's website at www.biodel.com which will link to a live webcast to be archived for 14 days.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. We develop our product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles.  For further information regarding Biodel, please visit the company's website at www.biodel.com.

BIOD-G

CONTACT: Seth Lewis, +1-646-378-2952

News Provided by Acquire Media


'/>"/>
SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Biodel Announces Name Change for Lead Product Candidate
2. InterMune to Present at Canaccord Adams Conference
3. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
4. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
5. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
6. Bionovo to Present at Canaccord Adams Global Growth Conference
7. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
8. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
9. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
10. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
11. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 Gene synthesis and ... has entered into a technology access and services ... apply DNA2.0’s proprietary protein engineering technology, known as ... “We are extremely excited that the global leader ... This proprietary bioengineering technology has now been validated ...
(Date:12/17/2014)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), ... commercialization of innovative therapeutics addressing cancer and other unmet ... commercial focus on China , today ... meeting with the U.S. Food and Drug Administration (FDA) ... 2015.  During this meeting the Company will seek guidance ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... ongoing Phase 2 pediatric study to evaluate once-weekly ... deficiency, or GHD.  This interim analysis consists of ... total enrollment in the study, completing all six ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... Chairman of Audit committee, TUSTIN, Calif., Nov. 5 ... announced today Mr. Douglas MacLellan has been elected by,its ... Officer and Executive,Chairman effective immediately. Mr. Michael Boswell has ... former role as Chairman of AMDL,s,Audit committee and long-standing ...
... Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ) today ... & Renshaw 10th Annual Healthcare Conference on,Tuesday, November ... will be held at,the New York Palace Hotel ... about this conference, please visit:, http://www.rodmanandrenshaw.com/conferences?id=19 , ...
... Mich., Nov. 5 InfuSystem,Holdings, Inc. (OTC Bulletin Board: ... pumps and associated clinical services,today announced financial results ... ended September 30, 2008., Mr. Steve Watkins, ... a solid 14.5% increase in revenue for the ...
Cached Biology Technology:AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO 2AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO 3AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO 4InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 2InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 3InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 4InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 5InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 6InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 7InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 8InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 9InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 10InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 11
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ... and bring LaunchKey to market in 2015. ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
(Date:12/11/2014)...  That blood pressure plays a role in human health ... medical term for high blood pressure – was first described ... cuff that,s used in measuring blood pressure was invented in ... about hypertension, its triggers and its effects. In fact, recent ... the best ways to treat it. For example, ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... Resveratrol, a compound in grapes, displays antioxidant and ... researchers at the UT Health Science Center San Antonio ... beneficial health effects. Resveratrol stimulates the expression of ... store fat, the team found. Adiponectin has a wide ...
... The bacterium which causes acne (Propionibacterium acnes) will be the ... Peter Lambert of Aston University. As well as acne, this ... is often ignored at diagnosis. Why are we not more ... length of stomach upsets and boost the immune system: , ...
... study that relates global energy use to economic growth, ... finds strong correlations between these two measures both among ... the study,s authors to infer that energy use limits ... in energy supply will be required to meet the ...
Cached Biology News:Grape ingredient resveratrol increases beneficial fat hormone 2Probiotics, prebiotics and biofuel-producing bacteria 2Study finds energy limits global economic growth 2
Collected from sexually mature, mixed sex, mixed breed guinea pigs. Pricing: $120/unit for 1 - 10 units...
Active GST Protein...
Marmoset plasma and serum - various quantities available...
Porcine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11...
Biology Products: